The elderly pancreas transplant recipient

Cancer in the transplant recipient.

Malignancy has become one of the three major causes of death after transplantation in the past decade and is thus increasingly important in all organ transplant programs. Death from cardiovascular disease and infection are both decreasing in frequency from a combination of screening, prophylaxis, aggressive risk factor management, and interventional therapies. Cancer, on the other hand, is poor...

Unusual manifestation of cutaneous Leishmaniasis in a renal transplant recipient

Cutaneous leishmaniasis may present as unusual manifestations in renal transplant patients receiving immunosuppressive therapy. This misleading presentation, may delay the diagnosis and treatment. Moreover special caution must be taken in renal transplant recipients because of possible interactions between antimony compounds and cyclosporine metabolites. We report a 45-year old man with 5 years...

Induction immunosuppressive therapy in the elderly kidney transplant recipient in the United States.

BACKGROUND AND OBJECTIVES The choice of induction agent in the elderly kidney transplant recipient is unclear. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS The risks of rejection at 1 year, functional graft loss, and death by induction agent (IL2 receptor antibodies [IL2RA], alemtuzumab, and rabbit antithymocyte globulin [rATG]) were compared among five groups of elderly (≥60 years) deceased...

Surgical Management of the Kidney Transplant Recipient

Pancreas Transplant Alone

The goal of this review is to highlight the significant improvements, over the past four decades, in outcomes after a pancreas transplant alone (PTA) in patients with brittle diabetes and recurrent episodes of hypoglycemia and/or hypoglycemic unawareness. A successful PTA-in contrast to intensive insulin regimens and insulin pumps-restores normoglycemia without the risk of hypoglycemia and prev...